VYNE Therapeutics
VYNE
55 hedge funds and large institutions have $63M invested in VYNE Therapeutics in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 20 increasing their positions, 22 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.25% less ownership
Funds ownership: 1.06% → 0.82% (-0.25%)
9% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 22
5% less funds holding
Funds holding: 58 → 55 (-3)
42% less capital invested
Capital invested by funds: $110M → $63M (-$46.5M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.15M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$225K |
| 3 |
BlackRock
New York
|
+$154K |
| 4 |
State Street
Boston,
Massachusetts
|
+$144K |
| 5 |
AIM
Alambic Investment Management
Belvedere,
California
|
+$114K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$24M |
| 2 |
DM
Deerfield Management
New York
|
-$443K |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$388K |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$367K |
| 5 |
JP Morgan Chase
New York
|
-$317K |
VYNE Hedge Fund Activity: Q3 2019 in Review
55 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q3 2019, worth a combined $63M — down 42% from $110M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of VYNE and 4 opened new positions — a net loss of 3 holders — while 22 trimmed existing stakes and 20 added.
The largest buyer was DAFNA Capital Management, adding an estimated $1.15M. The largest seller was Vivo Capital, exiting entirely with an estimated $24M sold.
- 55 institutional investors held VYNE Therapeutics (VYNE) as of Q3 2019, down from 58 in Q2 2019.
- Funds reported $63M of VYNE Therapeutics stock for Q3 2019, down 42% quarter-over-quarter.
- 4 funds opened new VYNE Therapeutics positions in Q3 2019 and 7 closed out, a net change of -3 holders.
- The largest VYNE Therapeutics buyer in Q3 2019 was DAFNA Capital Management, an estimated $1.15M added.
- The largest VYNE Therapeutics seller in Q3 2019 was Vivo Capital, an estimated $24M sold.
Based on aggregated 13F filings for Q3 2019.